NASDAQ:GNTA

Genenta Science (GNTA) Stock Price, News & Analysis

$3.10
-0.13 (-4.02%)
(As of 05/10/2024 ET)
Today's Range
$3.10
$3.30
50-Day Range
$2.55
$4.35
52-Week Range
$2.20
$6.81
Volume
17,777 shs
Average Volume
8,339 shs
Market Capitalization
$56.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Genenta Science MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Genenta Science in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.93) to ($1.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.29 out of 5 stars

Medical Sector

897th out of 925 stocks

Biological Products, Except Diagnostic Industry

151st out of 154 stocks

GNTA stock logo

About Genenta Science Stock (NASDAQ:GNTA)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

GNTA Stock Price History

GNTA Stock News Headlines

Genenta Science (NASDAQ:GNTA) Shares Down 2%
[Webinar] A Deep Dive into Options Volatility: Skew & Relative Value
Join us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand.
Genenta Science SpA Sponsored ADR
[Webinar] A Deep Dive into Options Volatility: Skew & Relative Value
Join us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand.
Genenta Science S.p.A. (GNTA)
Genenta Science S.p.A. ADR
See More Headlines
Receive GNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GNTA
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.21 per share

Miscellaneous

Free Float
12,936,000
Market Cap
$56.48 million
Optionable
Not Optionable
Beta
0.75
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Pierluigi Paracchi (Age 51)
    Vice Chairman of the Board, CEO & GM
  • Dr. Luigi Naldini M.D. (Age 65)
    Ph.D., Co-Founder & Chairman of the Executive Scientific Board
  • Dr. Bernard Rudolph Gentner M.D. (Age 49)
    Ph.D., Co-Founder & Member of the Executive Scientific Board
  • Mr. Richard B. Slansky (Age 66)
    Chief Financial Officer
  • Dr. Carlo Russo M.D. (Age 71)
    Chief Medical Officer & Head of Development
  • Dr. Stefania Mazzoleni Ph.D. (Age 42)
    Director of Program Development
  • Ms. Barbara Regonini (Age 51)
    Director of Finance

GNTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Genenta Science stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNTA shares.
View GNTA analyst ratings
or view top-rated stocks.

How have GNTA shares performed in 2024?

Genenta Science's stock was trading at $4.95 at the start of the year. Since then, GNTA stock has decreased by 37.4% and is now trading at $3.10.
View the best growth stocks for 2024 here
.

When did Genenta Science IPO?

Genenta Science (GNTA) raised $28 million in an initial public offering on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share.

How do I buy shares of Genenta Science?

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNTA) was last updated on 5/12/2024 by MarketBeat.com Staff

From Our Partners